- Home
- YHGJ vs CGTX Comparison
YHGJ vs CGTX Comparison
Compare YHGJ & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- CGTX
- Stock Information
- Founded
- YHGJ 1975
- CGTX 2007
- Country
- YHGJ United States
- CGTX United States
- Employees
- YHGJ N/A
- CGTX N/A
- Industry
- YHGJ Specialty Chemicals
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- CGTX Health Care
- Exchange
- YHGJ Nasdaq
- CGTX Nasdaq
- Market Cap
- YHGJ 14.0M
- CGTX 16.1M
- IPO Year
- YHGJ 1997
- CGTX 2021
- Fundamental
- Price
- YHGJ $0.57
- CGTX $0.68
- Analyst Decision
- YHGJ
- CGTX Strong Buy
- Analyst Count
- YHGJ 0
- CGTX 6
- Target Price
- YHGJ N/A
- CGTX $8.30
- AVG Volume (30 Days)
- YHGJ 24.2K
- CGTX 18.9M
- Earning Date
- YHGJ 02-19-2025
- CGTX 11-13-2024
- Dividend Yield
- YHGJ N/A
- CGTX N/A
- EPS Growth
- YHGJ N/A
- CGTX N/A
- EPS
- YHGJ N/A
- CGTX N/A
- Revenue
- YHGJ $18,559,000.00
- CGTX N/A
- Revenue This Year
- YHGJ N/A
- CGTX N/A
- Revenue Next Year
- YHGJ N/A
- CGTX N/A
- P/E Ratio
- YHGJ N/A
- CGTX N/A
- Revenue Growth
- YHGJ 11.78
- CGTX N/A
- 52 Week Low
- YHGJ $0.43
- CGTX $0.34
- 52 Week High
- YHGJ $1.85
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- YHGJ 47.71
- CGTX 51.83
- Support Level
- YHGJ $0.52
- CGTX $0.67
- Resistance Level
- YHGJ $0.62
- CGTX $0.76
- Average True Range (ATR)
- YHGJ 0.08
- CGTX 0.08
- MACD
- YHGJ 0.00
- CGTX -0.02
- Stochastic Oscillator
- YHGJ 41.61
- CGTX 9.12
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.